Breo ellipta
Pro Research Analysisby 
Searched over 200M research papers for "breo ellipta"
Breo Ellipta: A Comprehensive Overview
Introduction to Breo Ellipta
Breo Ellipta is an inhalation powder that combines fluticasone furoate, an inhaled corticosteroid (ICS), and vilanterol, a long-acting beta-2 adrenergic agonist (LABA). This combination is designed for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. The product is marketed by GlaxoSmithKline and Theravance under various brand names, including Breo in the USA and Relvar or Revinty in the EU 1234.
FDA Approval and Indications
COPD Treatment
Breo Ellipta received FDA approval for the maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. This approval marks it as the first long-term, once-daily medication for this purpose 13. The combination of fluticasone furoate and vilanterol helps to improve lung function and reduce the frequency of COPD exacerbations 13.
Asthma Management
In addition to COPD, Breo Ellipta is also approved for the treatment of asthma in adults and adolescents aged 12 years and older. The approval in the EU was based on phase 3 clinical trials that demonstrated its efficacy in improving pulmonary function and reducing severe asthma exacerbations 45. The once-daily administration of Breo Ellipta offers a convenient alternative to other ICS/LABA combinations that require twice-daily dosing, potentially improving patient adherence to treatment .
Mechanism of Action
Fluticasone Furoate
Fluticasone furoate is an inhaled corticosteroid that works by reducing inflammation in the airways, thereby decreasing the frequency and severity of asthma and COPD symptoms 34.
Vilanterol
Vilanterol is a long-acting beta-2 adrenergic agonist (LABA) that helps to relax the muscles around the airways, making it easier to breathe. When combined with fluticasone furoate, it provides a synergistic effect that enhances overall lung function 134.
Clinical Efficacy and Safety
COPD
Clinical studies have shown that Breo Ellipta significantly improves lung function in COPD patients. It is effective in reducing the frequency of exacerbations and improving overall quality of life 13.
Asthma
For asthma patients, Breo Ellipta has been found to be as effective as twice-daily fluticasone propionate/salmeterol and more effective than twice-daily fluticasone propionate alone. It also reduces the risk of severe asthma exacerbations and improves asthma control and quality of life measures 45.
Safety Profile
Breo Ellipta is generally well-tolerated, with a low incidence of systemic side effects due to the low systemic exposure of its components when administered via inhalation. This makes it a safe option for long-term use in both COPD and asthma patients .
Conclusion
Breo Ellipta represents a significant advancement in the treatment of COPD and asthma, offering a convenient once-daily dosing regimen that can improve patient adherence and overall treatment outcomes. Its combination of fluticasone furoate and vilanterol provides effective management of symptoms and reduces the frequency of exacerbations, making it a valuable addition to the available therapeutic options for these chronic respiratory conditions.
Sources and full results
Most relevant research papers on this topic
Fluticasone-vilanterol combination approved for COPD.
Breo Ellipta, is a long-acting 2-adrenergic agonist and fluticasone furoate inhaler for treating COPD in adults.
DOI